Johnson & Johnson $JNJ Stock Position Cut by Parr Mcknight Wealth Management Group LLC

Parr Mcknight Wealth Management Group LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 4.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 50,036 shares of the company’s stock after selling 2,391 shares during the quarter. Johnson & Johnson makes up about 1.6% of Parr Mcknight Wealth Management Group LLC’s investment portfolio, making the stock its 12th biggest position. Parr Mcknight Wealth Management Group LLC’s holdings in Johnson & Johnson were worth $13,247,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Jupiter Topco LLC bought a new position in shares of Johnson & Johnson during the second quarter worth about $1,967,399,000. Corient Private Wealth LP raised its holdings in shares of Johnson & Johnson by 127.3% during the second quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company’s stock valued at $1,539,292,000 after purchasing an additional 3,393,981 shares during the period. Wellington Management Group LLP raised its stake in Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after buying an additional 2,513,321 shares during the period. Amundi lifted its holdings in shares of Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Finally, SEB Asset Management AB acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth about $314,468,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Wall Street analysts remain moderately bullish on J&J’s prospects, according to a review of analyst views. Read article
• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares as part of a $175.3 million purchase that increased all 60 of the fund’s holdings. This indicates fund buying, but the report does not specify J&J’s allocation or suggest a company-specific investment view. Read article
• Neutral Sentiment: Smith+Nephew cut its outlook and confirmed failed merger discussions with J&J’s orthopedics unit. The talks’ failure removes a potential transaction, but the report does not detail any direct financial impact on J&J. Read article
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The announcement could create negative legal overhang, although it does not provide details about the claims or establish wrongdoing. Read article

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $276.62 on Thursday. The firm has a fifty day simple moving average of $265.67 and a two-hundred day simple moving average of $247.74. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $185.12 and a twelve month high of $282.02. The company has a market capitalization of $665.92 billion, a PE ratio of 41.91, a P/E/G ratio of 2.63 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Guggenheim reaffirmed a “buy” rating and set a $287.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 7th. Leerink Partners dropped their target price on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 14th. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Citigroup raised their price target on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Finally, Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $275.92.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.